No Data
No Data
CEO's Bold Move: Major Stock Purchase Signals Confidence in Aprea Therapeutics
Express News | Aprea Therapeutics Inc : Maxim Group Cuts Target Price to $10 From $16
Aprea Therapeutics Doses First Patient With HPV+ HNSCC In ACESOT-1051 Trial
Aprea Therapeutics Shares Are Trading Higher After the Company Announced It Has Commenced the Dosing of Patients With HPV+ Head and Neck Squamous Cell Carcinoma in Its Ongoing ACESOT-1051 Trial.
Express News | Aprea Therapeutics Inc -Open Label Data From Study Are Expected in Second Half of 2025
Express News | Aprea Therapeutics Reports Dosing of Patient With HPV+ Head And Neck Squamous Cell Carcinoma In Ongoing ACESOT-1051 Trial